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ABSTRACT
Purpose A 3D printer was used to realise compartmental
dosage forms containing multiple active pharmaceutical in-
gredient (API) formulations. This work demonstrates the mi-
crostructural characterisation of 3D printed solid dosage
forms using X-ray computed microtomography (XμCT) and
terahertz pulsed imaging (TPI).
Methods Printing was performed with either polyvinyl alcohol
(PVA) or polylactic acid (PLA). The structures were examined by
XμCT and TPI. Liquid self-nanoemulsifying drug delivery sys-
tem (SNEDDS) formulations containing saquinavir and
halofantrine were incorporated into the 3D printed
compartmentalised structures and in vitro drug release determined.
Results A clear difference in terms of pore structure between
PVA and PLA prints was observed by extracting the porosity
(5.5% for PVA and 0.2% for PLA prints), pore length and
pore volume from the XμCT data. The print resolution and
accuracy was characterised by XμCT and TPI on the basis of
the computer-aided design (CAD) models of the dosage form
(compartmentalised PVA structures were 7.5 ± 0.75% larger
than designed; n= 3).
Conclusions The 3Dprinter can reproduce specific structures
very accurately, whereas the 3D prints can deviate from the
designed model. The microstructural information extracted
by XμCT and TPI will assist to gain a better understanding
about the performance of 3D printed dosage forms.
KEY WORDS 3D printing . microstructure . polyvinyl
alcohol (PVA) . terahertz pulsed imaging (TPI) . X-ray computed
microtomography (XμCT)
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SWLI Scanning white light
interferometry
TPI Terahertz pulsed imaging
USP United states pharmacopeia
XOR-CAD Subvolume of the CAD data
which is not shared with the
XμCT volume
XOR-XμCT Subvolume of the XμCT
data which does not overlap
with the CAD model
XμCT X-ray computed microtomography
Y Vertical position
Ψ Azimuth angle
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INTRODUCTION
Over the last decade 3D printing of pharmaceuticals has gen-
erated growing interest in the academic community as well as in
the industry given the potential of the technology as a process-
ing platform for patient-centred dosage forms. In contrast to
traditional powder compaction, 3D printing enables imple-
mentation of totally new product design principles and changes
to dose and dosage form geometry can be achieved easily. The
recent product launch of SPRITAM, a 3D printed orally
disintegrating dosage form indicates that innovative
manufacturing principles, such as 3D printing are rapidly ma-
turing into a commercially feasible platform for drug produc-
tion (1,2). In addition to the new opportunities in the field of
patient-centred medicine it was demonstrated that it is possible
to develop in-vitro release characteristics for 3D printed tablets
beyond those possible for conventional tablets (3,4). Specific
designs enabling tailor-made drug release behaviour include
multilayer devices (3,5,6) or compartmental devices (5,7,8)
comprising a different active pharmaceutical ingredient (API)
in each layer or compartment. In the majority of applications
developed to date, the 3D printing process is carried out by
means of micro hot melt extrusion processes where molten
polymer (or polymer/drug mixture) is deposited layer-by-
layer to form a 3D object based on a computer aided design
(CAD) in a process called fused deposition modelling (FDM).
By careful design and selection of the filaments used for the
extrusion it is possible to print coating barriers suitable for a
range of immediate and modified-release applications (9).
However, while the structure and composition of the
resulting dosage form can be designed in many new and in-
novative ways it is important to systematically challenge the
applicability of existing quality control strategies for powder
compacts as defined in the respective pharmacopoeias for en-
suring the quality of 3D printed dosage forms. In a 3D printed
tablet the (micro) structure of the dosage form is defined by
design rather than being the result of the complex and hard to
control properties of granular particulate mixtures.
Furthermore, by definition batch release based on random
sampling cannot be applied for patient-centred dosage forms
in the traditional sense either. Although 3D printing has been
a research topic over the last decades there remains a gap in
understanding the impact of substrate materials, APIs, the
method of incorporating the API into the 3D printed structure
and the configuration of the printing process on the dosage
form performance. Fundamental measurements and under-
standing of these interactions are essential to develop quanti-
tative predictive models of the printing process and to guar-
antee a high product quality of every single dosage unit (10).
Given the unique ability to print extremely well defined
structures, and the role these structures play in the design of
the dosage form, it is clear that the microstructure will play a
central role to define the drug release characteristics, and
hence performance, for a 3D printed dosage form. In this
context it is useful to highlight that in principle any thermo-
plastic pharmaceutical excipient can be utilised as a substrate
material (filament), but that the print quality varies consider-
ably depending on for example the melting point, thermal
expansion coefficient, and elasticity of the filament as well as
a range of process parameters such as filament feed rate,
cooling rate and others (11). The impact of the structural
accuracy and integrity of printed structures for different
materials in the pharmaceutical context is relatively poorly
understood. Sandler et al. (12) used scanning white light inter-
ferometry (SWLI) to determine the thickness and roughness of
films of printed excipients and drug/excipient mixtures. They
also used the same technique to rapidly determine the struc-
ture and presence of defects in printed drug delivery systems.
Using this approach it was possible to separate layer structures
with thicknesses as small as 0.5 μm in polymer films, but the
method was not suitable to investigate samples with a thick-
ness of more than a few millimetres. However, for 2D printed
dosage forms SWLI proved a very powerful analytical
technique.
One promising method to characterise 3D printed struc-
tures is X-ray computed microtomography (XμCT). The
XμCT technique covers a range of spatial resolution, depend-
ing on sample size, of between 1-100 μm (13). Such a high
spatial resolution can be achieved due to the short wavelength
of X-rays and the availability of suitable detector arrays. Due
to their high energy, X-rays have the advantage of being able
to easily penetrate all pharmaceutically relevant excipients
while exhibiting negligible diffraction (14).
Employing XμCT to characterise 3D printed structures has
previously been performed in the field of scaffold-based tissue
engineering for example for the examination of the mechanical
deformation of 3D printed biodegradable poly(trimethylene
carbonate) scaffolds (15) and the characterisation of the bone
healing progress in calcium phosphate and collagen 3D printed
scaffolds (16). The biological functionality of engineered tissue is
highly influenced by architectural characteristics including po-
rosity, pore size, surface area to volume ratio, interconnectivity,
anisotropy, strut thickness (struts make up the interconnecting
scaffold framework), cross sectional area and permeability
(17,18). Most of these properties are of similar importance for
3D printed dosage forms (7,19). It was shown for 3D printed
poly-ε-caprolactone (PCL) scaffolds that XμCT is perfectly
suitable to analyse these characteristics like internal geometry,
porosity and interconnectivity of pores (20).
XμCT enables the investigation of microstructures in great
detail, but cannot be applied to control the microstructure of
every single dosage unit due to its long acquisition and recon-
struction time. An alternative to XμCT is terahertz pulsed
imaging (TPI) allowing for the acquisition of single depth-
resolved scans in a few milliseconds. TPI is a novel modality
for physical characterization of pharmaceutical drugmaterials
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and solid dosage forms (21). Terahertz radiation easily pene-
trates through most polymeric materials (22) making it an
attractive tool for non-destructive testing of pharmaceutical
products. Applications for TPI include the direct measure-
ment of coating thickness and the analysis of the uniformity
of pharmaceutical film coated tablets, structural imaging and
3D chemical imaging of solid dosage forms (14,23). In TPI,
the terahertz beam is focused onto the surface of the sample,
where the main part of the radiation is directly reflected by the
surface of the sample. A substantial fraction of the radiation
penetrates into the structure and is then reflected back by
subsequent interfaces separating two media with different re-
fractive indices. Distances can be determined by measuring
the delay time between the reflections of different structures
and considering the refractive index of the material under
investigation.
In this study we employed XμCT and TPI to qualitatively
and quantitatively analyse the microstructure of 3D printed
prototype solid dosage forms produced by FDM. Initially, the
concept of the characterisation using XμCT and TPI is pre-
sented using the example of a simple hollow cylindrical shape
dosage unit with one inner compartment prepared from two
different polymer filaments: polyvinyl alcohol (PVA) and
polylactic acid (PLA). The pore structure network is extracted
from XμCT data and further analysed in terms of porosity,
pore volume and pore length. In addition, the print resolution
and quality is examined on the basis of the co-registered CAD
model and the XμCT data of the dosage form. The same
analysis was then applied on a multi-compartmental dosage
unit filled with self-nanoemulsifying drug delivery system
(SNEDDS) formulations containing API. The microstructural
characteristics of the compartmental dosage forms were com-
pared to their drug release profiles.
MATERIAL AND METHODS
Materials
PVA and PLA f r om I n n o f i l 3D BV (Emmen ,
The Netherlands) were used as filaments for the printing of
cylindrical structures with one or two compartments (see
Fig. 1). Both filaments could be directly fed to the 3D printer.
The average filament thickness was 1.765 ± 0.012 mm (n=
20) and 1.702 ± 0.004 mm (n= 20) for the PVA and PLA,
respectively.
A complete list of all samples is provided in Table I. One
sample of the one-compartmental dosage unit was filled with
carbamazepine powder (CBZ, Hawkins, Inc., Minneapolis,
MN, USA). The two-compartmental dosage units were filled
with different liquids. The primary filling material was a
SNEDD system consisting of soybean oil from Sigma-
Aldrich (St. Louis, MO, US), Kolliphor® P 188 from BASF
(Ludwigshafen, Germany), Maisine 35-1 from Gattefossé
(Saint-Priest Cedex, France) and ethanol absolute from
VWR international (Fontenay-Sous-Bois, France). SNEDDS
containing saquinavir (0.05 g saquinavir / g SNEDDS) or
halofantrine (0.05 g halofantrine / g SNEDDS) were used as
filling material for the inner and outer compartment, respec-
tively. The free base forms of saquinavir and halofantrine
were both synthesized in-house from the hydrochloride salt.
Other chemicals, such as organic solvents and buffering re-
agents were of analytical grade and obtained from Merck
(Darmstadt, Germany) and Sigma-Aldrich (St. Louis, MO,
US). The other filling material was silicone oil, which was used
as a contrast agent for the XμCTmeasurements as it includes
atoms of significantly higher electron density than the
SNEDD system and thus more strongly absorbs X-rays (24).
3D Printing of Model Geometries
Cylindrical dosage forms with a single compartment (height:
7 mm, o.d.: 6.7 mm) and with two compartments (height:
10 mm, o.d.: 14 mm) were designed in Comsol Multiphysics
(Comsol, Stockholm, Sweden, v5.1). The 3DCADmodels are
illustrated in Fig. 1. The nominal thickness of the shell is
0.7 mm for the one- and 1.4 mm (same thickness for the inner
and outer shell) for the two-compartmental samples. In order
to 3D print the geometries the Comsol CAD files were con-
verted to binary STL (STereoLithography) files.
The samples were produced on a Makerbot Replicator 2
desktop 3D printer (New York, NY, US). This FDM printer
uses a thermoplastic filament, which is heated to its melting
point, extruded to produce a deposit strand with a width of
0.4 mm and a height of 0.3 mm. This deposit strand then
creates a 3D object layer by layer. A MakerBot Replicator 2
running on MakerWare software (Makerbot, New York, NY,
US, v 3.8.1) was configured with 100% infill and a 3D nozzle
print temperature of 230°C. The printing process was stopped
to enable the filling of the samples S03 with the CBZ and S07-
S12 with the liquid formulations. After filling the printing
Fig. 1 CAD schematics of cylindrical shape with one compartment (left) and
with a two-compartmental design (right).
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process was restarted to close the samples. A video showing
the 3D printing of a compartmental dosage form is available
in the online supplementary material.
Terahertz Pulsed Imaging (TPI)
The cylindrical shaped dosage forms were measured using a
commercial TPI system (Imaga 2000, Teraview Ltd.,
Cambridge, U.K.). Five hundred and twelve data points were
acquired for each terahertz time-domain waveform corre-
sponding to a depth of 3.45 mm in air. Such a single terahertz
time-domain waveform encodes information about the micro-
structure at one single point on the surface of the dosage form.
In order to analyse the whole dosage form, it is necessary to
point map across the entire surface of the sample. This is
performed by an automated terahertz tablet scanner, which
presents the dosage form at an angle of normal incidence to
the terahertz optics in order to avoid distortions of the wave-
forms due to refraction of the terahertz beam on the dosage
form surface. Therefore, the instrument generates a 3D di-
mensional model of the surface prior to the terahertz measure-
ments and further uses this model to present any point on the
surface of the sample at an angle of normal incidence to the
terahertz optics. The terahertz mapping is thus performed for
the top, bottom and side surface of the cylinder, whereas only
the side surface is examined in this study. The side surface is
described as a function of the azimuth angle (ψ) and the ver-
tical position (y) in cylindrical coordinates.
The waveforms were deconvolved mathematically to high-
light the structures and remove noise. The inverse filtering as
employed in TPI includes a division of the sample waveform
by the reference waveform in the frequency domain, which
amplifies any high frequency noise in the signal. Therefore,
the frequency domain division was coupled with a double
Gaussian filter to suppress these noise (25). The signal process-
ing of the waveforms was executed in Matlab (Mathworks
Inc., Natick, Massachusetts, USA, vR2016a) and the
deconvolved TPI data was visualised in Avizo Fire (FEI
Company, Hillsboro, Oregon, USA, v8.1).
X-ray Micro Computed Tomography (XμCT)
The 3D printed dosage forms were analysed using a SkyScan
1172 high-resolution XμCT scanner (Bruker, Antwerp,
Belgium). The SkyScan 1172 utilises a cone beam geometry
in combination with a 2D array detector. In this type of in-
strument the size of the sample and the resolution of the CCD
array are the limiting factors for the maximum achievable
spatial resolution given that shadow projects of the X-ray
transmissions are recorded. Smaller samples can be magnified
to a higher resolution. The samples were imaged at an isotro-
pic voxel resolution of 2.97 μm and 5.00 μm for the one- (S01
– S03) and the two-compartmental samples (S04 – S12), re-
spectively. 3D imaging is performed by rotating the object
through 180° with steps of 0.25° and recoding the projection
images (5 images were averaged per position) using the cone-
beam configuration. A total of 720 images were thus generat-
ed during a total acquisition time of about 1.5 h per sample.
The subsequent reconstruction using NRecon (Bruker,
v1.6.8.0) took about 30 min per sample. The data was
downsampled during the reconstruction to a voxel resolution
of 8.91 x 8.91 x 17.82 μm3 (924 x 924 x 405 pixels) and 14.99
x 14.99 x 28.98 μm3 (1060 x 1060 x 373 pixels) for the one-
(S01 – S03) and the two-compartmental samples (S04 – S12),
respectively. The downsampling was required to enable the
processing of the data in Avizo Fire.
The schematic in Fig. 2 illustrates the basic data flow and
used software for the acquisition and processing of the XμCT
Table I Listing of all Samples
Measured by XμCT ID Geometry Shell material Filling material
S01 One-compartment PVA Empty
S02 One-compartment PLA Empty
S03 One-compartment PVA CBZ
S04 Two-compartments PVA Empty
S05 Two-compartments PVA Empty
S06 Two-compartments PVA Empty
S07 Two-compartments PVA Silicon Oil (inner and outer compartment)
S08 Two-compartments PVA Silicon Oil (outer compartment)
S09 Two-compartments PVA Silicon Oil (inner compartment)
S10 Two-compartments PVA SNEDD system (inner and outer compartment)
S11 Two-compartments PVA SNEDD system (outer compartment)
S12 Two-compartmental PVA SNEDD system (inner compartment)
The samples S01 and S02 were also measured by TPI. The SNEDD system always contained saquinavir for the outer
and halofantrine for the inner compartment. The sample ID is used throughout this study. PVA - polyvinyl alcohol; PLA -
polylactic acid; CBZ – carbamazepine
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data. The processing consists of two main streams: (1) pore
network characterisation and (2) co-registration of the XμCT
and the CAD surface model of the 3D printed dosage forms.
The core algorithm for the extraction of the pore structure is
the watershed transform to separate touching objects in an
image. It assumes the image gradient as a topographic map
and finds catchment basins and watershed ridge lines. In order
to improve the extraction of the pore network, we applied a
marker-controlled watershed algorithm using defined fore-
ground and background regions.
The co-registration of the XμCT and CAD data (same
STL files as used for the printing) was conducted by applying
logical operators as described in Fig. 3. The aim of this pro-
cedure is to evaluate the performance of the printing process.
On the one hand, it identifies a subvolume of the XμCT data
(henceforth referred to as XOR-XμCT data), which does not
overlap with the CAD model. On the other hand, this ap-
proach is used to extract a subvolume of the CADdata (hence-
forth referred to as XOR-CAD data), which is not shared with
the XμCT volume.
Drug Release Testing
Drug release was experimentally determined by in-vitro release
testing using the basket method (USP 1) in HCl pH 1 on a
Erweka DT 70 (Heusanstamm, Germany) at 100 rpm and
37C and high-performance liquid chromatography (HPLC)
analysis was carried out on a UHPLC+ Dionex Ultimate
3000 Thermo Fischer Scientific (Waltham, MA, US) as
outlined previously (26). The drug release testing was per-
formed for the two-compartmental samples with the
SNEEDS formulation containing saquinavir in the outer
and halofantrine in the inner compartment. The release pro-
file is also compared to gelatine capsules filled with saquinavir.
RESULTS AND DISCUSSION
Characterisation of 3D Printed One-Compartmental
Geometries Using XμCT
Figure 4a shows the 3D rendering from the XμCT data of the
3D printed one-compartmental dosage form. The 3D render-
ing clearly illustrates the principle of FDM printing: the 3D
object is created layer-by-layer from bottom to top; every single
layer and the start of every flattened strand is noticeable in the
XμCT data. This dosage form contained CBZ powder and
thus the printing process was stopped to enable the filling.
The stop of the process is visible in the 3D rendering (slightly
below the cross-section label for Fig. 4b) as the diameter of the
cylinder shrank from 6.97 ± 0.12 mm (n = 6) to 6.61 ±
0.05 mm (n= 6). Interesting differences in the internal structure
of the polymer strands were observed: the cross-section image
in Fig. 4b, corresponding to a section of polymer that was
Fig. 2 Overview of the XμCT data processing. Each rectangular block represents one single processing unit and the rhombus shaped blocks correspond to input
or output data.
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printed after the filling step, exhibits a relatively homogenous
internal microstructure devoid or pores, which is in stark con-
trast to polymer structure that was printed before the filling step
(see Fig. 4c). The change of the pore structure can also be
observed in the 3D rendering by the rougher surface of the
3D print before the stop compared to the material printed after
the filling. This indicates that this 3D printing platform needs
some time to reach steady-state again and to produce a consis-
tent structure within the entire dosage form. It can be observed
towards the end of the printing run, i.e. at the top of the 3D
rendering in Fig. 4a, that the porosity of the polymer strand is
gradually increasing again. Figure 4b and c further visualise the
CBZ particles inside the 3D print. The volume weighted mean
particle size of the CBZ powder is about 12 μm and the struc-
tural domains that are visible in the cross-section images repre-
sent agglomerates of CBZ particles. In general, this type of
analysis could be used to validate the internal fill volume as well
as to evaluate particle agglomeration.
A detailed investigation of the pore structure within the
wall polymer strands was conducted for the empty PLA and
PVA samples. In these samples the pore structure is consistent
over the entire 3D printed structure as there was no filling step
and the process was not stopped. Figure 5 highlights a clear
difference between the PLA and PVA samples in terms of
number of pores and pore lengths. In particular, long tube-
like pore structures form between each layer when PLA is used
as a filament. The deposit strand width is 0.4 mm (the hard-
ware parameter of the printer is set by the extrusion nozzle
diameter) and therefore the printer uses two strands to build
each layer of the wall (target thickness 0.7 mm). The tube-like
pores are located between the two neighbouring strands and
between each successive layer. Such pores are not present in
the print when PVA is used as the filament. However, the use
of PVA results in a more complex pore structure network of
much higher porosity formed by smaller pores (Table II). The
pores in the PVA samples exhibit high connectivity and hence
appear as clusters in Fig. 5e. However, the Watershed algo-
rithm also separates a high number of small pores from the
connected pores leading to a high standard deviation (SD) of
the mean pore volume for the PVA filament. Using these data
the total porosity can be determined (fraction of void volume
to total volume) yielding 5.5% and 0.2% for the PVA and
PLA samples, respectively. The quantities in Table II high-
light the significant difference in terms of the internal micro-
structure between the two filament materials. In addition,
Fig. 5a and b further reveal that there are voids between the
start and the end of each strand in each layer indicating a
systematic defect of the dosage unit, which might act as a weak
spot to containment of any filling and where dissolution me-
dium might be able to penetrate more quickly into the dosage
form. These voids are more pronounced in PLA than in PVA
samples.
The volumes of the XOR-XμCT (red) and XOR-CAD
(blue) data, as given in Table II, were computed from the
co-registered images (Fig. 6). The XOR-XμCT volume indi-
cates the excess of material and the XOR-CAD volume
Fig. 3 Schematic of the co-
registration of XμCTand CAD data.
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Fig. 5 Analysis of pore structure of (a,b,c) PLA and (d,e,f) PVA shells on the basis of XμCT data. (b) and (e) illustrates only the pores, where a colour depending
on the pore length was assigned to each connected pore. (c) and (f) are y-z cross-section images of the PLA and PVA shell, respectively. The colour map is valid for
all subfigures.
Fig. 4 Visualisation of XμCT data of sample S03 (cylindrical PVA shell filled with CBZ). (a) 3D visualisation of XμCT data. (b, c) x-y cross-section images from the
positions as denoted in (a).
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reveals the material that is missing in the 3D printed structure.
The aim of this analysis is to quantify the printing accuracy
relative to the ideal CAD model, which was utilised to guide
the printing process, and can be further applied to optimise
the printing. The volume of the 3D printed PVA sample is
smaller than it was designed to be due to the large pore
Fig. 6 Co-registration of the 3D rendering of the XμCT images and the CADmodel. The blue color visualises the XOR-CAD data and the red color represents
the XOR-XμCT data. (a,b,c) are 3D printed using PLA and (d,e,f) represent the XμCTresults of the PVA shells. The online supplementary material contains two
videos of the co-registered XμCT data and CAD model of the samples S01 and S02
Table II Characteristic
Microstructural Properties of the
Empty One-Compartmental PVA
(Sample S01) and PLA Shells
(Sample S02)
S01 S02
Weight mg 145.2 161.3
Porosity % 5.5 0.2
Mean pore volume mm3× 104 2.70 ± 141.80 3.80 ± 4.00
Mean pore length mm 0.04 ± 0.09 0.20 ± 0.72
Shell thickness (n=6) mm 1.11 ± 0.05 0.99 ± 0.10
Deposit layer thickness mm 0.27 ± 0.03 0.28 ± 0.01
XOR-CAD volume mm3 38.6 15.1
XOR-XμCT volume mm3 32.7 33.9
Total XμCT volume mm3 108.6 129.1
XOR-CAD volume / CAD volume % 33.7 13.7
XOR-XμCT volume / CAD volume % 28.5 30.7
XμCT volume / CAD volume % 94.8 117.1
The total CAD volume is 115.07 mm3 . The total volume of the XμCT in the table is the volume without the void
spaces. The difference between the XOR-XμCT volume / CAD volume and XOR-CAD volume / CAD ratios is
approximately the same as XμCT volume / CAD volume – 100. The deposit layer thickness is the vertical layer height,
which should be nominally the same as the deposit strand height of 0.3 mm
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volume, although it appears larger in Fig. 6. The PVA shell is
about 59% thicker than designed, whereas the PLA shell
thickness increases in average by 41%. Moreover, the defi-
ciency ratio (XOR-CAD volume / CAD volume) is signifi-
cantly lower for the PLA sample due to the smaller pore vol-
ume and this also leads to a larger ratio between the total
XμCT and the CAD volume.
Microstructural Characterisation
of the One-Compartmental Samples Using TPI
One of the key challenges in patient-centred medicine is the
quality control of each single dosage unit. Although XμCT
provides very detailed information about the microstructure
used to identify defects in the 3D print, it is unfeasible to
control every single printed dosage form due to its long acqui-
sition and reconstruction times (>1 hour). TPI could act as an
alternative quality control tool providing fast acquisition of
depth profiles (<1 s) and thus enabling the control of a much
higher number of samples. However, the interpretation of the
terahertz waveforms is more complex and prior knowledge
based on the XμCT measurements has to be developed in
order to relate the TPI data to microstructural properties
relevant for quality control.
3D renderings from the TPI data (Fig. 7) indicate differ-
ences between microstructure of the PVA and PLA samples.
In accordance to the XμCT measurements, a more complex
network of pores is visible in the PVA (Fig. 7a and b) than in
the PLA (Fig. 7c and d) samples. The supplementary informa-
tion additionally presents peak intensity maps of two samples,
which clearly highlight defects on the surface (i.e., low peak
intensity) of the dosage forms. The peak intensity is strongly
affected by the refractive index of the surface and can thus be
used to analyse relative density changes. The terahertz mea-
surements therefore provide additional information about the
quality of the dosage forms, as such strong variations of the
surface were not observed in the XμCT data. Furthermore,
terahertz imaging allows to control the shell thickness, which
directly impacts the drug release kinetics, in a non-destructive
and contactless manner. The measured shell thickness values
are 1.12 ± 0.05mm (n= 6) for the PVA (refractive index of 1.6
(27)) and 0.86 ± 0.02 mm (n= 6) for the PLA (refractive index
of 1.89 (28)) shells, which are in good agreement with the
thickness measurements from XμCT (see Table II).
The quantitative interpretation of the terahertz data is not
straightforward as the terahertz pulses are focused to a diffrac-
tion limited spot of 200 μm diameter to the surface of the
printed dosage form. This configuration is specifically de-
signed to investigate relatively thin subsurface structures such
as film coating layers that extend to a depth of several hundred
micrometres in z-direction at most. Given the penetrative
power of terahertz radiation into the polymer materials used
to print the structures it is possible to extract further structural
information at depth from the data. The results clearly show
that the inside wall of the printed structure can be resolved
comfortably at depth > 1.5 mm. However, due to the increas-
ing dispersion of the focused pulses at depth as well as the
relatively strong scattering given the size of the pore structure
it would be premature to draw full conclusions on the appli-
cability of TPI for quantitative porosity analysis in such dosage
forms. There is clearly a significant potential of this technique
for such applications, which remains to be explored and which
might require adjustments both to the terahertz optics, as well
as the signal processing and data extraction routines that go
beyond the remit of this proof-of-principle study.
Characterization of Empty 3D Printed
Two-Compartmental Geometries
Consequently, the internal structure of the more complex 3D
printed two-compartmental geometries was only assessed by
XμCT. The same analysis procedure as outlined in the pre-
vious section was conducted for the two-compartmental sam-
ples and the results are summarised in Table III. For these
samples the actual sample volumes were found to be 7.5%±
0.75 SD (n= 3) larger than the design. It is interesting to note
that the volume of the cylindrical PVA samples was signifi-
cantly smaller compared to the CAD volume, even though the
porosity is similar in all cases. The different geometries might
impact on the total volume as indicated by the deficiency (i.e.
XOR-CAD/CAD volume) and excess ratios (i.e. XOR-
XμCT/CAD volume) and we note that the difference be-
tween the two ratios is smaller, even negative, for the cylindri-
cal compared to the compartmental samples. Furthermore,
both the inner and outer shell thicknesses are considerably
above the nominal value of 1.4 mm (36%) resulting in more
excess material. This is in good agreement with several other
studies (16,29) indicating a systematical deviation of the 3D
print from the CAD model.
As outlined previously, the printer with the configuration
used for this study can only produce shell thicknesses with a
discrete step size of 0.4 mm, which is limited by the physical
width of the deposited printed strand. The 2-compartmental
shells were produced by four adjoined strands yielding a wall
thickness of 1.6 mm for each shell. The fact that the layer
thickness in z-direction (see Table III) is slightly smaller
(0.29 mm) than the nominal value of 0.3 mm (which was the
chosen layer height) indicates that the strand deforms under its
own weight causing an increase of the wall thickness in hori-
zontal dimension by 13.3% (4(0.30–0.29)/0.30) for sample
S04 using four strands in one layer) due to its contraction in
vertical direction. This would yield a shell thickness of
1.90 mm (1.6 mm (1 + 0.133 + 0.0477) considering the mea-
sured porosity of 4.77% (for sample S04), which is in good
agreement with the measured shell thickness. Based on the
understanding of the dimensional changes due to gravity
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and porosity extracted from the results the CAD file could be
modified to account for the volumetric changes of thematerial
in order to produce more accurate prints. A modification of
the process to achieve the desired dimensions of the 3D print
could be performed by developing a predictive model which
enables the selection of a suitable manufacturing procedure
(including the design of the CAD model and process param-
eters), as proposed by Boschetto and Bettini (30).
Fig. 7 3D TPI data of (a,b) empty PVA shells (sample S01) and (c,d) empty PLA shells (sample S02). The bottom layer in each 3D image corresponds to the air/
shell interface. Coordinate system: Psi is the azimuth angle in accordance to a cylindrical coordinate system; y corresponds to the vertical position on the cylindrical
shaped sample; z is the depth coordinate considering a refractive index of 1
Table III Characteristic




Weight g 1.3119 1.3230 1.2959
Porosity % 4.77 4.85 4.89
Mean pore volume mm3 × 104 6.10 ± 355.00 6.29 ± 40.00 4.96 ± 266.66
Mean pore length mm3 0.09 ± 0.19 0.08 ± 0.18 0.09 ± 0.16
Outer shell thickness (n=6) mm 1.90 ± 0.08 1.92 ± 0.10 1.86 ± 0.09
Inner shell thickness (n=6) mm 1.96 ± 0.09 1.92 ± 0.08 1.90 ± 0.08
Deposit layer thickness mm 0.29 ± 0.01 0.29 ± 0.01 0.28 ± 0.01
XOR-CAD volume mm3 167.18 161.86 176.13
XOR-XμCT volume mm3 233.05 245.13 273.58
Total XμCT volume mm3 1199.54 1199.92 1214.16
XOR-XμCT / CAD volume ratio % 20.80 21.88 24.42
XOR-CAD / CAD volume ratio % 14.92 14.45 15.72
XμCT / CAD volume % 107.08 107.12 108.39
The total CAD volume is 1220.2 mm3 . The same relationships between the different quantities apply as described in
Table II. The online supplementary material contains a video of the co-registered XμCT data and CAD model used to
calculate the XOR-CAD and XOR-XμCT volumes of sample S04
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However, the variation between repeated prints of the
same design is very small and the microstructural parameters
as listed in Table III are overall in very good agreement be-
tween samples. The small shell thickness variationsmight orig-
inate from the thickness variation of the PVA filament itself
(9), which has an average thickness of 1.765 ± 0.012 mm (n=
20). Our results show that this printing technology provides a
high reproducibility of the output for repeated prints of the
same design. At the same time the results highlight that the
accuracy of the production of a specific CAD model highly
depends on the material properties of the feed materials and
the design of the printed geometry. In particular, a thorough
understanding of the rheology of the filament is necessary to
produce high quality prints (31).
Characterization of Filled 3D Printed
Two-Compartmental Geometries
The 3D printed two-compartmental structures were filled
with silicon oil or with SNEDDS containing an API. The
XμCT rendering of these samples are visualised in Fig. 8.
The results show that the filling material cannot be easily
differentiated from the polymer, in particular for the case
where the liquid is loaded into the outer shell. However, areas
with a different contrast are visible in Fig. 8h, which is as-
sumed to be the SNEDDS (samples without filling did not
contain this contrast, data not shown). In order to test this
hypothesis we examined samples filled with silicon oil in order
to artificially enhance the contrast in the X-ray shadow im-
ages. The presence of Si in silicon oil provides a significant
difference in electron density compared to the SNEDDS and
the polymer and thus makes it easier to distinguish the liquid
from the PVA structures. This is illustrated in Fig. 9 where the
silicon oil can be clearly distinguished from the PVA. The
images show that the liquid is distributed in a similar fashion
within the inner and outer compartment as the SNEDDS
depicted in Fig. 8, albeit with higher contrast.
The XμCT renderings of filled samples indicate that the
liquid exhibits a high attraction to the shell walls. In the inner
compartment the fluid covers the entire surface and does not
fill the open space from bottom to top as one might expect. A
capillary pressure induced by the porous system might exert a
force on the fluid, which facilitates penetration into the porous
system. The surface tension of the oil then further causes the
formation of an air bubble in the centre of the void which in
turn results in the full coverage of the PVA shell surface.
However, due to the high viscosity of the liquid the capillary
pressure is too small to exert a sufficient force on the fluid that
would result in deeper penetration of the oil phase into the
porous structure or even an efflux of the fluid. A similar phe-
nomenon can be observed Fig. 9b, e and h when the oil is
placed into the outer compartment: the fluid is attracted to the
shell surfaces that exhibit the largest curvature. This allows for
the fluid to acquire the least surface area possible and yields
menisci that cover the top and the bottom internal surface
within the outer compartment.
In order to calculate the liquid volume, we converted the
XμCT volume to binary data (Fig. 10). The threshold required
for the conversion of the XμCT volumes to binary data was set
on the basis of including the shell material and the silicon oil in
the converted material. Slight variations of the threshold were
not critical as the silicon oil could be readily observed in the y-z
cross-sections (i.e. the bright regions) in Fig. 10a and c. Upon
comparison of Fig. 10a, c with b, d it is clear that the converted
binary data covers the PVA shell and the silicon oil. Therefore,
the volume of the liquid in each compartment can be deter-
mined by subtracting the average volume of the empty struc-
tures from the total XμCT volumes (see Table IV for S08 and
S11). Such analysis results in a volume of 56 mm3 and 58 mm3
for the case of the silicon oil in samples S08 and S09, respec-
tively and, more importantly, a volume for the SNEDD system
of 35 mm3 and 54 mm3 for samples S11 and S12, respectively.
The liquid volume of the samples filled in both compartments
are 101 mm3 (S07, silicon oil) and 97 mm3 (S10, SNEEDS).
The current processing procedure provides only a total liquid
volume and cannot differentiate between the volume from the
inner and outer compartment. The separation of the liquid
from different compartments as well as from the polymer will
be implemented for future studies, which will also improve the
accuracy of the volume measurement. However, these results
are in surprisingly good agreement with the actual loading
amount of 50 μl of liquid in each compartment, especially when
taking into consideration the limited resolution of the used
XμCT setup, the use of an average volume of the empty struc-
ture as well as the low contrast between SNEEDS and the
polymer. Based on these results we conclude that XμCT can
be used to measure the volume of loaded SNEDDS within the
compartmental dosage forms. The analysis further validates
Table IV Properties calculated from the XμCTand CAD data for samples
S08 (compartmental sample filled with silicon oil in the outer compartment)
and S11 (compartmental sample filled with SNEDDS containing saquinavir in
the outer compartment)
S08 S11
XOR-CAD volume mm3 121.8 153.1
XOR-XμCT Volume mm3 266.1 276.1
Total XμCT volume mm3 1261.0 1239.7
XOR-XμCT volume / total CAD volume % 23.8 24.7
XOR-CAD volume / total CAD volume % 10.9 13.7
XμCT volume / CAD volume % 112.6 111.0
Volume of fill material mm3 56.4 35.1
The volume of the fill material is calculated by subtracting the average total
XμCT volume of 1204.54 mm3 of samples S04 – S06 from the total XμCT
volume of the respective sample containing the liquid
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that the liquid stays within the dosage form and does not diffuse
significantly through the porous shell.
API Release of Compartmental Dosage Unit
The amount and combination of the SNEDDS containing
APIs depends on the patients’ drug combinatorial needs and
dose requirements. The release behaviour from the SNEDDS
loaded two-compartmental printed dosage unit is contrasted
to the release from conventional gelatine capsules. During
dissolution testing it was observed that the two-compartment
3D printed dosage forms exhibited a considerable delay in
release of API compared to release of API from gelatine cap-
sules. As expected, the release of halofantrine from the inner
Fig. 8 Subvolumes of the two-compartmental geometries filled with a SNEDD system generated from the XμCT data. The brighter regions correspond to the
SNEDDS, which are noticeable in the outer and inner compartment (sample S10) in (a), (d) and (g), only in the outer compartment (sample S11) in (b), (e) and
(h), and only in the inner compartment (sample S12) in (c), (f) and (i).
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compartment commenced only after approximately 240 mi-
nutes where roughly 80% of the saquinavir from the outer
compartment was already released (Fig. 11).
The drug release characteristics are directly impacted by
many factors such as the microstructural properties of the
PVA shells. The mass transport of the dissolution medium
and the drug might be driven by a pressure gradient (typically
referred to as Darcy flow (32)), by an activity gradient (case II
relaxation) or by a combination of both. Pressure and activity
gradient are considerably impacted by microstructural prop-
erties of the shell pore structure (33). The total flux is highly
affected by the properties of the porous structure (e.g., shell
Fig. 9 Subvolumes of the two-compartmental geometries filled with silicon oil generated from the XμCT data. The brighter regions correspond to the silicon oil,
which is visible in the outer and inner compartment (sample S07) in (a), (d) and (g), only in the outer compartment (sample S08) in (b), (e) and (h), and only in the
inner compartment (sample S09) in (c), (f) and (i). The online supplementary material shows a video of sample S07
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thickness, permeability, diffusivity, porosity, tortuosity and
connectivity of the pores), the properties of the fluid (e.g.,
pH, viscosity, temperature) and properties of the fluid/
porous system (e.g., contact angle/wettability) (34). The re-
lease of halofantrine from the inner compartment will be fur-
ther delayed (210min) as the dissolutionmedium and the drug
Fig. 10 3D renderings of two
different subvolumes of the same
sample S08 (compartmental sample
filled with silicon oil in the outer
compartment). The volumes are
binary data (0 – air, 1 - material)
converted from the XμCT data by
setting a threshold. Both pairs (a,b)
and (c,d) present the same
subvolume, where (a,c) additionally
depicts the y-z cross-section from
the original XμCT volume. The
bright regions in the cross-section
images (a,c) correspond to the sili-
con oil, which are also part of the
binary data as depicted in (b,c). The
liquid volume is thus included in the
calculation of the material volume of
the binary data.
Fig. 11 Drug release of APIs from
gelatine capsules and 3D printed
compartmental geometry filled with
SNEDDS containing saquinavir in
the outer compartment and
halofantrine in the inner
compartment. (n=3, mean±
standard error of the mean).
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have to pass two shells. Furthermore, the inner compartment
exhibits a smaller surface area compared to the outer com-
partment which further reduces the API flux.
Moreover, the XμCT analysis indicates a strong wetting
behaviour of the liquid formulation and the polymer wall
leading to a significant adhesive force between the two mate-
rials. The dissolution medium and the lipid formulation have
a far less attractive relationship. These surface interactions of
the liquid formulation influence the release rates of saquinavir
and halofantrine: In the outer compartment there are two
surfaces for the liquid formulation to interact with while there
is only one in the inner compartment and the inner compart-
ment has as smaller surface area than the outer compartment.
The wettability also influences the forces (capillary and dif-
fusion), which cause the penetration of the dissolutionmedium
into the dosage form and the release of the liquid formulation
out of the dosage form. The low release rate at the beginning
(<150min for the outer compartment in Fig. 11) indicates that
the droplet diffusion of the SNEDD system is a slow process.
During the experiment, erosion of the wall will also contribute
to the diffusion (35). Erosion will change the pore structure in
the shell by increasing the porosity with increasing dissolution
time. This will further affect the interconnectivity of the pores
and eventually facilitate the formation of micro-channels and
late on actual channels. A capillary force builds up in these
micro-channels causing a faster release process (>150 min for
outer compartment in Fig. 11).
The different release kinetics between the two compartments
can also be analysed by fitting a power law y= ktm (with y as the
dissolved API% and t as the dissolution time) to the release data.
This yields the fit parameters m= 0.80 and k = 0.88 for saquin-
avir and m= 0.63 and k = 3.29 for halofantrine. We only con-
sidered the release data of halofantrine above 210min to reflect
the release kinetics without the delay. The difference in expo-
nent m indicates that the fundamental release processes are





-dependent release process. The large difference in k is
mainly due to erosion of the inner shell during the release of the
liquid from the outer shell.
Themass transportmechanisms involved in the disintegration
and erosion process might be different for the same materials
when 3D printed than when compressed to a tablet. During
compaction tablet constituents are subject to plastic and elastic
deformation before interparticulate bonds are forged (36). The
reversible viscoelastic process of deformation, i.e. strain recovery,
is one of the key mechanisms involved in the disintegration and
erosion process of a tablet in theGI tract (37,38). Since there is no
deformation of particles during 3D printing, strain recovery
might not have any significant effect on the release behaviour
of 3D printed solid dosage forms. Therefore, drug release behav-
iours of specific formulations cannot be directly translated to 3D
printed products, even for dosage forms based on the same for-
mulation. More research has to be conducted to better
understand the drug release mechanisms involved in 3D printed
dosage forms. A deeper understanding of the drug release mech-
anisms and the possibility to easily design product geometries are
key elements for the future product design with increasing imple-
mentation of in silico principles (39).
CONCLUSION
This study demonstrated the capability of using XμCT to
develop a knowledge base for 3D printed solid dosage forms.
A full exploitation of FDM and the relevant pharmaceutical
applications requires a detailed examination of the printed
microstructure in order to eventually manufacture consistent
and high quality products. XμCT is highly suitable to char-
acterise the architecture of the 3D print as well as to verify the
print resolution, print quality and to confirm the added drug
volume amount. The ease, speed and limited safety concerns
of TPI compared to XμCT renders it a feasible platform for
quality control of 3D printed patient-centred medicines in
future. However, more research has to be performed to ex-
tract the essential information about the microstructure from
the terahertz waveforms, which is limited at present.
3D printed compartmentalised formulations allow tailor-
ing the in-vitro release profile of the respective drugs in the
SNEDD system to target different parts of the GI tract. In
particular, the microstructural information extracted by
XμCT will assist to gain a better understanding about the
release kinetics of 3D printed dosage forms. However, it is
evident that this formulation mitigates targeted release of
SNEDDS containing API to the GI tract and that patient-
centred medicines may be produced by this approach. A
change of API and/or formulation composition can be done
using this approach without affecting the printing process,
which is not the case if the API is incorporated into the fila-
ment prior to printing. Furthermore, the fact that the API is
spatially decoupled from the 3D printing of the filament limits
the API exposure to elevated temperatures and is subsequent-
ly a desirable attribute of this approach. In conclusion this
work shows that 3D printing can be used to produce
patient-centred combinatorial drug products with different
release and dosing properties depending on the patients’ need.
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